March 12, 2012
Novo Nordisk Pharma announced on March 9 that it filed an application in Japan on the same day for the fixed-dose combination treatment of the ultra-long-acting insulin degludec and the ultra-fast-acting insulin aspart. The agent has been developed as a...read more